Georgia Bio, Nationwide Life Science Leaders Unite To Celebrate Continued Investment In Biotech At New York Stock Exchange

Industry leaders from across the country to ring NYSE closing bell and kick off Biotech Month

FOR IMMEDIATE RELEASE

January 4, 2024, New York, NY – Georgia Bio, the life sciences trade association in Georgia, joined 16 fellow life science trade organizations from across the country yesterday to ring the closing bell at the New York Stock Exchange (NYSE) and kick off national Biotech Month. Maria Thacker-Goethe, immediate past chair for the Council of State Bioscience Associations (CSBA) and President and CEO of Geogia Bio, was among the leaders in attendance at the event, which was held jointly by NewYorkBIO and NYSE to celebrate the link between investment and innovation to best serve patients nationwide.

Council of State Bioscience Associations (CSBA) and the Biotechnology Innovation Organization (BIO) Rings The Closing Bell® The New York Stock Exchange welcomes the Council of State Bioscience Associations (CSBA) and the Biotechnology Innovation Organization (BIO), today, Wednesday, January 3, 2023, in celebration of of Biotechnology Month. To honor the occasion, John Conrad, President of Illinois Biotechnology Innovation Organization (iBIO), and Maria Thacker Goethe, President of Georgia Bio, joined by Michael Harris, Global Head of Capital Markets, NYSE, rings the Closing Bell®. Photo Credit: NYSE
Photo Credit: NYSE

“I’m honored to ring the closing bell at the New York Stock Exchange with the new CSBA chair, John Conrad of iBio,” said Thacker-Goethe. “Joining my colleagues from across the country underscores that collaboration will help us protect and grow the U.S. innovation ecosystem.”

Georgia is poised to be a hub for life sciences. Georgia Bio’s workforce development program guarantees that the State’s workforce will be well-equipped to meet the demands of the expanding life science community. On the investment side, Georgia Bio along with 6 southeast state associations have partnered with Life Science Nation to launch RESI South in Atlanta on March 25. RESI South will mark the first-even life sciences investor event in the region and will connect start-ups and early-stage investors, an opportunity to showcase the state’s numerous investment opportunities.

“Nationwide collaboration is crucial to driving innovation, finding cures, and ultimately improving health outcomes and quality of life for patients,” added Jennifer Hawks Bland, CEO of NewYorkBIO. “As the worldwide epicenter for the financial sector, New York is uniquely positioned as a nexus for connecting the biosciences industry with the capital that makes groundbreaking research and development possible. NewYorkBIO is grateful to NYSE for this opportunity to welcome our colleagues from across the country to Wall Street, as we bring new meaning to ‘ringing in the new year’ and kick off Biotech Month.”

The event is one of several ongoing collaborations between NewYorkBIO and NYSE, who work together to connect New York’s robust investor community with innovative life science organizations of all types and sizes.

“We are thrilled to host NewYorkBIO and life sciences leaders from across the U.S. at the NYSE to ring our Closing Bell in honor of Biotechnology Month,” said Michael Harris, Global Head of Capital Markets at the New York Stock Exchange. “As we continue to see growth in the life sciences industry, the NYSE looks forward to welcoming many more biotech companies to our community of icons and disruptors.”

Maria Thacker-Goethe joined the below leaders from life science organizations across the country:

  • Nick Shipley, Chief Advocacy Officer at BIO
  • Michele Oshman, Vice President for External Affairs at BIO
  • Chris Molineaux, President & CEO of Life Sciences Pennsylvania
  • Debbie Hart, President & CEO of BioNJ
  • Jennifer Hawks Bland, CEO, NewYorkBIO
  • Elyse Blazevich, President & CEO of Colorado BioScience Association
  • Eddie Pauline, President & CEO of Ohio Life Sciences
  • Jodie Gillon, President & CEO of BioCT
  • John Conrad, President & CEO of Illinois Biotechnology Innovation Organization
  • Joni Ekstrum, Executive Director of South Dakota Biotech
  • Kelly Schulz, CEO of Maryland Tech Council
  • Kendalle Burlin O’Connell, President & CEO of MassBio
  • Laura Gunter, President of North Carolina Life Sciences Organization
  • Michael Fleming, President of Delaware BioScience Association
  • Mike Guerra, President & CEO of California Life Sciences

First introduced by President Clinton in 2000, National Biotechnology Month is an opportunity for the nation’s biotech community to come together to recognize the industry’s achievements on behalf of patients around the world. Falling in January, the recognition month is also an opportunity for industry leaders to look ahead to the advancements of the upcoming year.

To capture the closing bell on January 3, refer to NYSE’s website: nyse.com/bell/calendar

About Georgia Bio

Georgia Bio (GaBio) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For more than 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. For more information, visit www.gabio.org.

Contact

Jason Rupp, Georgia Bio, jrupp@gabio.org

January 20, 2026
January 20, 2026. Paulding County has been designated a BioReady Silver Community by Georgia Life Sciences, the state’s leading life sciences membership organization. The BioReady designation recognizes communities that demonstrate strong zoning practices, infrastructure capacity, and readiness to support biotechnology and life sciences development. “We are proud to recognize Paulding County as our newest BioReady Silver community,” said Maria Thacker-Goethe, President and CEO of Georgia Life Sciences. “Paulding County’s proactive planning, growing workforce, and access to regional healthcare and transportation infrastructure position it well to support life sciences manufacturing and commercialization. Through the BioReady program, we champion communities that are intentionally preparing to compete for industry investment and job growth.” Paulding County’s designation reflects its commitment to thoughtful land-use planning, scalable infrastructure, and business-friendly development policies that support life sciences and advanced manufacturing uses. Located in the northwest Atlanta metro region, the county offers access to a strong labor pool, major transportation corridors, and regional healthcare systems, making it an attractive option for biotechnology, medical device, diagnostics, and related life sciences companies seeking room to grow. “Georgia BioReady designation validates Paulding County’s readiness to support bioscience investment and strengthens our position as a growing hub for advanced industries,” said Alex Almodovar, President & CEO, Paulding County Economic Development Inc. & Industrial Building Authority The BioReady rating system evaluates communities across three tiers—Bronze, Silver, and Gold—based on their readiness to attract and support life sciences facilities. Through these ratings, Georgia Life Sciences helps municipalities better showcase biotech-appropriate sites, strengthen infrastructure planning, and clearly identify life sciences-friendly locations. This approach enables communities like Paulding County to compete more effectively for private investment and high-quality job creation. Georgia Life Sciences advances innovation, strengthens the workforce pipeline, and grows Georgia’s life sciences economy through the BioReady Community program, modeled after MassBio’s nationally recognized rating system, which assesses a community’s readiness to host life sciences facilities based on zoning practices and infrastructure capacity. About Georgia Life Sciences Georgia Life Sciences, founded in 1989, is a non-profit, membership-based organization that promotes the interests and growth of the life sciences industry. It is the state’s largest and most influential life sciences advocacy and business leadership organization working to improve access to innovative discoveries that have lifesaving impact. The association connects business, academia, government, and other allied entities involved in the application of life sciences products to fuel growth and collaboration through policy development, community programs, national industry initiatives, and a portfolio of educational and networking events. Learn more at galifesciences.org.
January 14, 2026
What happens when students see real work before choosing a future 
January 8, 2026
By: Patrick Plues | RealClearHealth January 8, 2026 For decades, America has led the global biotech industry – thanks, in part, to state-level policies that encourage research and manufacturing investments. But other countries, including China, are sparing no expense in the bid to overtake us. Beijing has officially made biotechnology a national strategic priority and is pouring billions into state-backed research and manufacturing efforts. All states should consider impactful biotech policies that grow and strengthen our domestic biotechnology industry. If states fail to utilize and replicate what are considered to be the best and most successful policies in biotech-focused economic development, the United States will soon lose its long-term leadership in developing medicines and medical technologies, which underpin our health, our economy, and our national security. Thankfully, many governors and state legislatures around the country are already answering this call -- as our new study, The U.S. Bioscience Industry: A Powerful Engine for State Economies, demonstrates. Keep Reading at https://www.realclearhealth.com/2026/01/08/americas_biotech_leadership_depends_on_the_states_1157584.html
MORE POSTS